Transplant Recipients Faced Varied Cancer Risk Levels
A large study found lung transplant patients had higher risks for certain cancers compared to those who received kidney transplants.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that current transplant aftercare sufficiently monitors patients for long-term cancer risks?
Researchers analyzed data from 622,330 organ transplant recipients between 2000 and 2023 to identify cancer incidence patterns. The study revealed that lung transplant recipients, in particular, face higher rates of solid tumors and posttransplant lymphoproliferative disorder.
Why it matters
Understanding these varied cancer risks is critical as the need for long-term malignancy monitoring intensifies for transplant patients. These findings suggest that the intensity of required immunosuppressive therapy may play a significant role in long-term health outcomes.
In a study of 622,330 patients, researchers found that 8% were diagnosed with one cancer, while 4,909 patients developed at least two malignancy types. Nonmelanoma skin cancers accounted for 54.9% of all identified malignancies.
The details
The study compared cancer rates across heart, kidney, liver, and lung transplant recipients. Researchers suggest that the increased malignancy rates, particularly for lung and heart recipients, likely stem from the higher intensity of immunosuppressive medications required to prevent organ rejection. Over a 10-year follow-up period, incidence rates for specific cancers including lung, bladder, colorectal, and genital malignancies were shown to rise.
Timeline
Patients received transplants between 2000 and 2023.
U.S. solid organ transplants increased by over 50 percent between 2013 and 2024.
The maximum follow-up period for malignancy diagnosis in the study was 10 years.
Health Landscape
As transplantation becomes more common, evidenced by a 50 percent increase in U.S. solid organ transplants between 2013 and 2024, long-term survival monitoring has become a primary clinical priority. This research provides a new benchmark for assessing malignancy risks among diverse transplant populations.
If you are a transplant recipient, it is important to maintain consistent cancer screenings as part of your post-transplant care plan. Discuss the specific monitoring schedule recommended for your transplant type with your transplant team, especially regarding risks like nonmelanoma skin cancer.
The takeaway
Organ transplant recipients face elevated risks for certain malignancies, partly linked to the immunosuppression required for their procedure. Prioritize regular follow-up appointments with your specialist to track long-term health metrics and discuss appropriate screening intervals.
Further reading
For more on evolving research regarding malignancies, visit the Cancer section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that current transplant aftercare sufficiently monitors patients for long-term cancer risks?
